by George Institute for Global Health Credit: Unsplash/CC0 Public Domain The latest findings from the PROTECT phase III trial show sparsentan—a novel treatment for IgA nephropathy—significantly reduces proteinuria, or abnormal protein levels in the urine, compared to standard treatment irbesartan. The interim analysis of data from the PROTECT trial was published April 1 in The Lancet and simultaneously...